Glatiramer acetate (GA) and beta-interferons (IFN beta) collectively comprise the BRACE treatments (Betaseron®, Rebif®, Avonex®, Copaxone®, Extavia®), which are widely approved as disease-modifying therapies (DMTs) for MS. This evidence concerns the gene IFNB1 and myeloid sarcoma.